Search alternatives:
significant changes » significant challenge (Expand Search)
significant cause » significant change (Expand Search), significant increase (Expand Search), significant decrease (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), mean decrease (Expand Search)
significant changes » significant challenge (Expand Search)
significant cause » significant change (Expand Search), significant increase (Expand Search), significant decrease (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), mean decrease (Expand Search)
-
1
Increased or reduced ATGL-1 activity does not significantly change <i>N. parisii</i> growth.
Published 2025Subjects: -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
10
Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
11
Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
12
Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
13
Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
14
Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
15
Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
16
Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
17
Change in STAI scores after counseling.
Published 2025“…There was a trend of increased recall rates in group 2 for short-term problems, long-term problems, intervention, and incidence rates, but it did not reach statistically significant level. There was an overall decrease in State Trait Anxiety Inventory (STAI) scores of participants after counseling (p = 0.002) but no statistically difference in change of STAI scores between the two groups (p = 0.981).…”
-
18
-
19
-
20
Change in Mean Anxiety Scores Over time by group.
Published 2025“…There was a trend of increased recall rates in group 2 for short-term problems, long-term problems, intervention, and incidence rates, but it did not reach statistically significant level. There was an overall decrease in State Trait Anxiety Inventory (STAI) scores of participants after counseling (p = 0.002) but no statistically difference in change of STAI scores between the two groups (p = 0.981).…”